Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on EquityReturn on Sales

Summit Therapeutics (SMMT) EBITDA Margin (2016 - 2024)

Historic EBITDA Margin for Summit Therapeutics (SMMT) over the last 7 years, with Q2 2024 value amounting to 1945.04%.

  • Summit Therapeutics' EBITDA Margin changed N/A to 1945.04% in Q2 2024 from the same period last year, while for Sep 2025 it was 4.95004644540416e19%, marking a year-over-year decrease of 4.95004644540416e23%. This contributed to the annual value of 11131.63% for FY2022, which is 63220700.0% down from last year.
  • Summit Therapeutics' EBITDA Margin amounted to 1945.04% in Q2 2024.
  • Summit Therapeutics' 5-year EBITDA Margin high stood at 1946.25% for Q1 2020, and its period low was 9742.73% during Q3 2022.
  • For the 3-year period, Summit Therapeutics' EBITDA Margin averaged around 1114.62%, with its median value being 1668.99% (2024).
  • The largest annual percentage gain for Summit Therapeutics' EBITDA Margin in the last 5 years was 5211800bps (2020), contrasted with its biggest fall of 5211800bps (2020).
  • Summit Therapeutics' EBITDA Margin (Quarter) stood at 1946.25% in 2020, then plummeted by -601bps to 9742.73% in 2022, then skyrocketed by 120bps to 1945.04% in 2024.
  • Its last three reported values are 1945.04% in Q2 2024, 1392.95% for Q1 2024, and 9742.73% during Q3 2022.